Detalhe da pesquisa
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37674077
2.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38507751
3.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med
; 386(12): 1143-1154, 2022 03 24.
Artigo
Inglês
| MEDLINE | ID: mdl-35320644
4.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36495879
5.
Culturally adapted translation of LYMPH-Q upper extremity module from English to Mandarin Chinese.
J Formos Med Assoc
; 2024 Jan 08.
Artigo
Inglês
| MEDLINE | ID: mdl-38195319
6.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36493792
7.
Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma.
Breast Cancer Res
; 25(1): 11, 2023 01 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36707876
8.
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Cancer Sci
; 114(1): 221-226, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36168844
9.
A Novel Injection Protocol Using Voluven®-Assisted Indocyanine Green with Improved Near-Infrared Fluorescence Guidance in Breast Cancer Sentinel Lymph Node Mapping-A Translational Study.
Ann Surg Oncol
; 30(13): 8419-8427, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37605084
10.
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
BMC Cancer
; 23(1): 865, 2023 Sep 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37710198
11.
High rate of postoperative upstaging of ductal carcinoma in situ when prioritizing ultrasound evaluation of mammography-detected lesions: a single-center retrospective cohort study.
World J Surg Oncol
; 21(1): 48, 2023 Feb 17.
Artigo
Inglês
| MEDLINE | ID: mdl-36804000
12.
The effect of immediate lymphatic reconstruction on the post-operative drain output after axillary lymph node dissection for breast cancer: A retrospective comparative study.
Microsurgery
; 43(6): 555-562, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-36762663
13.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med
; 380(7): 617-628, 2019 02 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30516102
14.
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.
Breast Cancer Res Treat
; 192(3): 593-602, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35138529
15.
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
Breast Cancer Res Treat
; 192(3): 629-637, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35113257
16.
Perceived Causes of Cancer and Corresponding Behavioral Changes: A Qualitative Study on Breast Cancer Survivors in Taiwan.
Cancer Control
; 29: 10732748221132522, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36192670
17.
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
Future Oncol
; 2022 Oct 21.
Artigo
Inglês
| MEDLINE | ID: mdl-36268941
18.
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders.
J Formos Med Assoc
; 121(12): 2538-2547, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-35752529
19.
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
Breast Cancer Res Treat
; 187(3): 759-768, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-33860389
20.
Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.
Jpn J Clin Oncol
; 51(3): 345-353, 2021 Mar 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33619550